Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

of less than 70 mg/dL. For Moderately High-Risk patients, the target is less than 130 mg/dL. Over 20 million people in the U.S. in the High-Risk and Moderately High-Risk categories are failing to meet recommended LDL-C targets using currently available lipid-lowering therapies.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of ISIS 301012 in treating high cholesterol. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a b
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/19/2014)... 2014 According to market ... Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, ... Rotary) & Geography - Global Trends & Forecast ... the lyophilization market on the basis of various ... of the market size of each of these ...
(Date:9/19/2014)... 19, 2014  Lpath, Inc. (NASDAQ: ... therapeutics, announced today that it has entered into ... common stock and 3,605,042 unregistered warrants in a ... one registered share of common stock and one ... common stock will be $3.475.  The warrants have ...
(Date:9/19/2014)... LONDON , September 19, 2014 ... hat Pharma IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, ... abdeckt. Die interaktive PDF, verfügbar unter pharmaserialisation.com ... an dem sie jeweils in Kraft treten. ... der Serialisierung nicht länger um das "ob", sondern ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
(Date:9/19/2014)... 2014 Unbound , an international humanitarian ... regions of the Philippines being affected by both a tropical ... families evacuated to the nearest public schools while others moved ... and gusty winds to portions of the northern Philippines. ... homes filled with more than 10 feet of water. ...
(Date:9/19/2014)... Phoenix, AZ (PRWEB) September 19, 2014 Hastings ... over 30 years in the industry, announces a record number ... firm handles a wide variety of serious injury cases as ... cases along with dog bite related accident cases and others. ... Hastings and Hastings has stood the test of time when ...
(Date:9/19/2014)... U.S. military troops deployed to sunny climates may have ... new study. Many returning troops reported getting ... military personnel developed blisters on their skin or noticed ... their moles since being deployed overseas. All of ... the study authors noted. "The past decade of ...
(Date:9/19/2014)... Alan Mozes HealthDay Reporter ... Cancer patients burdened by stress and family conflicts before ... their operation, a new study suggests. Investigators found ... have a nearly three times greater risk for complications ... of life. "We,ve long known that patient quality ...
(Date:9/19/2014)... Pittsburgh, PA (PRWEB) September 19, 2014 ... I fear getting wrinkles due to stretching the skin ... from Anniston, Ala. "This inspired me to design a ... HANDS-FREE EYE CONTACT LENS SYSTEM provides a quicker, easier, ... eliminates the need to perform this task manually, saves ...
Breaking Medicine News(10 mins):Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3
... , WASHINGTON, June 23 Today the 400,000-strong ... Manufacturers of America (PhRMA) for its commitment to ... 50 percent for seniors who fall into the ... Phillips, RetireSafe President, called the commitment, "a huge ...
... disorders are frequently seen as psychological or societal,diseases, but ... study,shows that the levels of a brain protein differ ... and occasionally fatal eating disorder most commonly,affecting women. Scientists ... some studies suggest a link to low levels of ...
... Derma Sciences, Inc. (OTC Bulletin Board: ... today that it has begun shipping BIOGUARD(TM) Barrier Dressings ... has been awarded reimbursement codes for the dressings, allowing ... will offer surgeons, wound care clinicians, infection control experts ...
... Pa., June 23 The Department of Health has received ... Housing and Urban Development, or HUD, to implement a new ... in Erie and Philadelphia. , , "The Healthy ... housing related hazards for children such as mold, radon, and ...
... ... Vivacare has included medication rebate coupons and medication brochures as ... the needs of physicians and patients, and improve medication adherence. 69% ... help them to fill their medication at the pharmacy. 86% of ...
... /PRNewswire-Asia/ -- Wan (Corporate Services) Ltd., the,sole agent of Perrier in Hong ... Perrier. , Perrier Clarifies ... We strongly believe the Consumer Council Findings is not correct. , ... Nitrite in Perrier is,not correct. , Nitrite content ...
Cached Medicine News:Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 2Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 3Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 4Health News:Pennsylvania Department of Health Receives Recovery Funds for New Healthy Homes Program 2Health News:Vivacare Patient Education Service Includes Medication Rebates and Brochures to Improve Medication Adherence 2Health News:Vivacare Patient Education Service Includes Medication Rebates and Brochures to Improve Medication Adherence 3Health News:Perrier Clarifies the NITRITE Level in Consumer Council Findings 2
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
... provide a broad selection of ... a wide variety of ophthalmic ... is packaged sterile, complete with ... switch in the "off " ...
... provide a broad selection of ... a wide variety of ophthalmic ... is packaged sterile, complete with ... switch in the "off " ...
Medicine Products: